<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00444912</url>
  </required_header>
  <id_info>
    <org_study_id>AMD31002113</org_study_id>
    <nct_id>NCT00444912</nct_id>
  </id_info>
  <brief_title>The Effect of Rituximab on Mobilization With AMD3100 (Plerixafor) Plus G-CSF in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) or Hodgkin Disease (HD)</brief_title>
  <official_title>A Pilot Cohort Study of AMD3100 in Combination With G-CSF and Rituximab Compared With AMD3100 in Combination With G-CSF Alone for Mobilization of BPCs in Patients With Relapsed or Refractory NHL or HD Prior to Autologous HPC Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Participants with non-Hodgkin lymphoma (NHL) or Hodgkin disease (HD) will be assigned to one
      of 2 arms based on the immunophenotype of their lymphoma.

      (A)Participants with CD20(-) lymphoma will undergo mobilization with granulocyte
      colony-stimulating factor (G-CSF) and plerixafor.

      (B) Participants with CD20(+) lymphomas will undergo mobilization with rituximab, G-CSF, and
      plerixafor. They will receive a weekly dose of rituximab beginning 1 week prior to, and
      continuing until 2 weeks after, the first dose of G-CSF.

      Participants in both groups will receive G-CSF twice daily for 4 days. In the evening on Day
      4, a dose of plerixafor will be administered. Apheresis will be initiated the next morning.
      Participants will continue to receive G-CSF twice daily and to receive the evening dose of
      plerixafor followed by apheresis the next morning for up to a total of 4 aphereses or until
      ≥5*10^6 CD34+ cells/kg are collected.

      Participants who are transplanted will be monitored for the time to polymorphonuclear
      leukocytes (PMN), platelets (PLT), and lymphocyte engraftment. Follow-up assessments will be
      done at 100 days, and 6 and 12 months post-transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, 2-arm, non-randomized, open-label study to evaluate the safety of
      plerixafor when used in combination with rituximab (Rituxan®) and granulocyte
      colony-stimulating factor (G-CSF) in patients with relapsed or refractory Hodgkin disease
      (HD) or non-Hodgkin lymphoma (NHL).

      Participants will be assigned to one of 2 arms based on the immunophenotype of their
      lymphoma.

      (A)Participants with CD20(-) lymphoma will undergo mobilization with G-CSF and plerixafor.

      (B) Participants with CD20(+) lymphomas will undergo mobilization with rituximab, G-CSF, and
      plerixafor. They will receive a weekly dose of 375 mg/m2 rituximab by intravenous (iv)
      infusion beginning 1 week prior to, and continuing until 2 weeks after, the first dose of
      G-CSF.

      Participants in both groups will receive 7.5 µg/kg G-CSF twice daily (morning and evening)
      for 4 days. In the evening (approximately 10:00 pm) on Day 4, a dose of plerixafor (240
      µg/kg) will be administered. Apheresis will be initiated the next morning, approximately 10
      to 11 hours after plerixafor is given. Participants will continue to receive G-CSF twice
      daily and to receive the evening dose of plerixafor followed by apheresis the next morning
      for up to a total of 4 aphereses or until ≥5*10^6 CD34+ cells/kg are collected.

      Participants with an adequate number of autologous peripheral blood stem cells (PBSCs)
      collected by apheresis will be admitted to the study center for the administration of
      high-dose chemotherapy and autologous transplantation. After transplantation, the times to
      PMN, PLT, and lymphocyte engraftment will be measured. Participants will remain hospitalized
      until they achieve an absolute granulocyte count of &gt;500/µl in the peripheral blood. Graft
      durability will be assessed at 100 days, and 6 and 12 months post-transplantation.

      This study was previously posted by AnorMED, Inc. In November 2006, AnorMED, Inc. was
      acquired by Genzyme Corporation. Genzyme Corporation is the sponsor of the trial.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Summary of Adverse Events (AEs)</measure>
    <time_frame>Day 1 and up to Day 59 (maximum time before start of chemotherapy)</time_frame>
    <description>Number of participants with adverse events (AEs) collected from Day 1 (start of G-CSF mobilization in participants with CD20- lymphoma or start of rituximab in participants with CD20+ lymphoma) to the day before starting chemotherapy. AEs were graded by the investigator using the World Health Organization (WHO) Adverse Event Grading Scale and were assessed for seriousness and relatedness to study treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median Cumulative Number of CD34+ Cells Collected During Apheresis</measure>
    <time_frame>Days 5-8</time_frame>
    <description>Median total number of CD34+ cells collected during apheresis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Fold Increase in the Number of CD34+ Cells After Plerixafor Administration</measure>
    <time_frame>Days 4-5</time_frame>
    <description>Fold Increase = (Pre-Apheresis CD34+ cells/Pre-Plerixafor CD34+ cells).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Number of Apheresis Days Required to Reach a Minimum of 3*10^6 CD34+ Cells/kg</measure>
    <time_frame>Days 5-8</time_frame>
    <description>Median number of apheresis days in each treatment arm to collect a minimum of 3*10^6 CD34+ cells/kg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Number of Apheresis Days Required to Reach the Target of 5*10^6 CD34+ Cells/kg</measure>
    <time_frame>Days 5-8</time_frame>
    <description>Median number of apheresis days in each treatment arm to reach the target of 5*10^6 CD34+ cells/kg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Number of Days to Polymorphonuclear Leukocyte (PMN) Engraftment</measure>
    <time_frame>Days post transplantation (approximately Day 40)</time_frame>
    <description>Median number of days from transplantation to PMN engraftment which was defined as PMN counts ≥0.5*10^9/L for 3 consecutive days or ≥1.0*10^9/L for 1 day. Time to engraftment corresponded to the first day that the criteria were met.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Number of Days to Platelet (PLT) Engraftment</measure>
    <time_frame>Days post transplantation (approximately Day 40)</time_frame>
    <description>Median number of days from transplantation to PLT engraftment which was defined as platelet counts ≥20*10^9/L without transfusion for the preceding 7 days or platelet counts ≥50*10^9/L for one day. Time to engraftment corresponded to the first day that the criteria were met.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Number of Days to Lymphocyte Engraftment</measure>
    <time_frame>Days post transplantation (approximately Day 40)</time_frame>
    <description>Median number of days from transplantation to lymphocyte engraftment which was defined as lymphocyte counts ≥5*10^8/L. Time to engraftment corresponded to the first day that criteria were met.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Level of CD19+CD2-CD14- B-cells Six Months Post-Transplant</measure>
    <time_frame>Approximately 7 months (6 months post-transplant)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Level of CD19+CD2-CD14- B-cells Twelve Months Post-Transplant</measure>
    <time_frame>13 months (12 months post-transplant)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Percentage of CD19+CD3-CD14- B-cells of the Total Cells on the First Apheresis Day</measure>
    <time_frame>Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Durable Engraftment 12 Months After Transplantation</measure>
    <time_frame>Approximately 13 months (12 months post-transplant )</time_frame>
    <description>The number of participants maintaining a durable graft 12 months after autologous transplantation. A durable graft is defined as the maintenance of normal blood counts.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Non-Hodgkin Lymphoma</condition>
  <condition>Hodgkin Disease</condition>
  <arm_group>
    <arm_group_label>G-CSF plus plerixafor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with CD20- lymphoma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>G-CSF plus plerixafor and rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with CD20+ lymphoma</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-CSF plus plerixafor</intervention_name>
    <description>Participants underwent mobilization with G-CSF (7.5 µg/kg twice daily) for 4 days, administered by subcutaneous (sc) injection. On the evening of Day 4, participants received a dose of plerixafor (240 µg/kg), administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF (7.5 µg/kg) and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor. Participants were to continue to receive G-CSF twice daily and to receive the evening dose of plerixafor followed by apheresis the following morning for a maximum of 4 aphereses or until ≥ 5*10^6 CD34+ cells/kg were collected.</description>
    <arm_group_label>G-CSF plus plerixafor</arm_group_label>
    <other_name>AMD3100</other_name>
    <other_name>Mozobil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-CSF plus plerixafor</intervention_name>
    <description>Participants underwent mobilization with G-CSF (7.5 µg/kg twice daily) for 4 days, administered by subcutaneous (SC) injection. On the evening of Day 4, participants received a dose of plerixafor (240 µg/kg), administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF (7.5 µg/kg) and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor. Participants were to continue to receive G-CSF twice daily and to receive the evening dose of plerixafor followed by apheresis the following morning for a maximum of 4 aphereses or until ≥5*10^6 CD34+ cells/kg were collected.</description>
    <arm_group_label>G-CSF plus plerixafor and rituximab</arm_group_label>
    <other_name>Mozobil</other_name>
    <other_name>AMD3100</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rituximab</intervention_name>
    <description>Participants were given a weekly dose of rituximab 375mg/m2 by intravenous infusion for 1 week prior to and continuing until 2 weeks after the first dose of G-CSF.</description>
    <arm_group_label>G-CSF plus plerixafor and rituximab</arm_group_label>
    <other_name>Rituxan</other_name>
    <other_name>MabThera</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (abbreviated list):

          -  Histological diagnosis of diffuse large cell lymphoma, B-cell, T-cell or anaplastic
             histologies; peripheral T-cell lymphoma; small non-cleaved Burkitt-like lymphoma; or
             Hodgkin disease. NOTE: Participants diagnosed at a facility outside of Emory
             University will have their diagnosis confirmed by Emory University pathologists prior
             to being enrolled in this study.

          -  Eligible for autologous transplantation.

          -  History of relapse of lymphoma following initial treatment with an
             anthracycline-containing regimen or disease that is refractory or progresses during
             initial therapy with an anthracycline-containing regimen.

          -  Immunophenotyping of the lymphoma at the time of diagnosis or relapse using flow
             cytometry or immunohistochemistry.

          -  Presence of clinically- and/or radiologically-documented, measurable, and/or evaluable
             disease at the time of relapse.

          -  Received 2 cycles of salvage chemotherapy.

          -  Complete response (i.e., normal physical examination, lymph nodes, lymph node masses,
             and bone marrow) or a partial response (i.e., decrease of ≧50% in the size of lymph
             nodes or lymph node masses or decrease in size of liver/spleen on physical exam) to at
             least one cycle of a salvage chemotherapy regimen.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.

          -  Absolute granulocytes count ≧1.0*10^9/l.

          -  Platelet count ≧75*10^9/l.

          -  Aspartate aminotransferase (AST) or alanine transaminase (ALT) ≦2.5 times the upper
             limit of normal (ULN) or ≦5 times the ULN if liver involvement with lymphoma.

          -  Life expectancy of at least 3 months.

          -  &gt;4 weeks since last cycle of chemotherapy.

          -  Patient has recovered from all acute toxic effects of prior chemotherapy.

          -  Signed informed consent.

        Exclusion Criteria (abbreviated list):

          -  A second active malignancy (other than basal cell carcinoma of the skin).

          -  Uncontrolled central nervous system involvement by lymphoma.

          -  Positive/history of retroviral infection (HIV, HTLV-1).

          -  Active infection requiring antibiotics during planned lymphoma-related therapy.

          -  Previous treatment with high-dose chemotherapy or cytokine mobilization and
             hematopoietic progenitor cell transplantation.

          -  Continued evidence by morphology and flow cytometry of bone marrow involvement after
             at least one cycle of salvage chemotherapy.

          -  ≥3 cycles of salvage chemotherapy following documentation of lymphoma relapse or
             disease progression.

          -  (In patients with CD20(+) lymphoma) History of severe hypersensitivity reactions to
             rituximab.

          -  Positive pregnancy test in female patients.

          -  Lactating female patients.

          -  Previously received experimental therapy within 4 weeks of enrolling in this protocol
             or currently enrolled in another experimental protocol during G-CSF Mobilization
             Phase.

          -  Creatinine &gt;1.5 times the ULN.

          -  Bilirubin &gt;1.5 times the ULN.

          -  Ejection fraction &lt;45%.

          -  Diffusion capacity of the lung for carbon monoxide (DLCO) &lt;50%.

          -  Patients of childbearing potential unwilling to implement adequate birth control.

          -  A co-morbid condition that renders the patient at high risk from treatment
             complications.

          -  Residual acute medical condition resulting from prior chemotherapy.

          -  Documented history of ventricular arrhythmias during the last 3 years.

          -  Fever (temperature &gt;38 °C/100.4 °F).

          -  Actual body weight exceeds 175% of ideal body weight.

          -  Participants who have deterioration of their clinical status or laboratory parameters
             between the time of enrolment and transplant (such that they no longer meet entry
             criteria) may be removed from study at the discretion of the treating physician,
             principal investigator, or sponsor.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Genzyme, a Sanofi Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2007</study_first_submitted>
  <study_first_submitted_qc>March 7, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2007</study_first_posted>
  <results_first_submitted>June 25, 2010</results_first_submitted>
  <results_first_submitted_qc>June 25, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 29, 2010</results_first_posted>
  <last_update_submitted>February 10, 2014</last_update_submitted>
  <last_update_submitted_qc>February 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AMD3100</keyword>
  <keyword>stem cell mobilization</keyword>
  <keyword>autologous transplant</keyword>
  <keyword>Non-Hodgkin Lymphoma</keyword>
  <keyword>Hodgkin Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
    <mesh_term>JM 3100</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>G-CSF and Plerixafor</title>
          <description>Participants with CD20- lymphoma received granulocyte colony-stimulating factor (G-CSF) and plerixafor</description>
        </group>
        <group group_id="P2">
          <title>G-CSF and Plerixafor + Rituximab</title>
          <description>Participants with CD20+ lymphoma received rituximab, G-CSF, and plerixafor</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Plerixafor</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Transplant</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant Failed Mobilization</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>G-CSF and Plerixafor</title>
          <description>Participants with CD20- lymphoma received granulocyte colony-stimulating factor (G-CSF) and plerixafor</description>
        </group>
        <group group_id="B2">
          <title>G-CSF and Plerixafor + Rituximab</title>
          <description>Participants with CD20+ lymphoma received rituximab, G-CSF, and plerixafor</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.3" spread="11.3"/>
                    <measurement group_id="B2" value="46.5" spread="14.9"/>
                    <measurement group_id="B3" value="42.9" spread="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African-American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic/Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Disease Diagnosis</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hodgkin disease (HD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Hodgkin lymphoma (NHL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Summary of Adverse Events (AEs)</title>
        <description>Number of participants with adverse events (AEs) collected from Day 1 (start of G-CSF mobilization in participants with CD20- lymphoma or start of rituximab in participants with CD20+ lymphoma) to the day before starting chemotherapy. AEs were graded by the investigator using the World Health Organization (WHO) Adverse Event Grading Scale and were assessed for seriousness and relatedness to study treatment.</description>
        <time_frame>Day 1 and up to Day 59 (maximum time before start of chemotherapy)</time_frame>
        <population>Safety Population: all participants who received at least 1 dose of study drug (G-CSF, plerixafor, or rituximab)</population>
        <group_list>
          <group group_id="O1">
            <title>G-CSF and Plerixafor</title>
            <description>Participants with CD20- lymphoma received granulocyte colony-stimulating factor (G-CSF) and plerixafor</description>
          </group>
          <group group_id="O2">
            <title>G-CSF and Plerixafor + Rituximab</title>
            <description>Participants with CD20+ lymphoma received rituximab, G-CSF, and plerixafor</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Adverse Events (AEs)</title>
          <description>Number of participants with adverse events (AEs) collected from Day 1 (start of G-CSF mobilization in participants with CD20- lymphoma or start of rituximab in participants with CD20+ lymphoma) to the day before starting chemotherapy. AEs were graded by the investigator using the World Health Organization (WHO) Adverse Event Grading Scale and were assessed for seriousness and relatedness to study treatment.</description>
          <population>Safety Population: all participants who received at least 1 dose of study drug (G-CSF, plerixafor, or rituximab)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants Reporting at Least 1 AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participant Count of Mild AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participant Count of Moderate AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participant Count of Severe AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participant Count of Life-Threatening AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs by Relationship - Not Related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs by Relationship - Probably Not Related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs by Relationship - Possibly Related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs by Relationship - Probably Related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs by Relationship - Definitely Related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Cumulative Number of CD34+ Cells Collected During Apheresis</title>
        <description>Median total number of CD34+ cells collected during apheresis.</description>
        <time_frame>Days 5-8</time_frame>
        <population>Full Analysis Set (FAS) includes all participants who received at least 1 dose of plerixafor.</population>
        <group_list>
          <group group_id="O1">
            <title>G-CSF and Plerixafor</title>
            <description>Participants with CD20- lymphoma received granulocyte colony-stimulating factor (G-CSF) and plerixafor</description>
          </group>
          <group group_id="O2">
            <title>G-CSF and Plerixafor + Rituximab</title>
            <description>Participants with CD20+ lymphoma received rituximab, G-CSF, and plerixafor</description>
          </group>
        </group_list>
        <measure>
          <title>Median Cumulative Number of CD34+ Cells Collected During Apheresis</title>
          <description>Median total number of CD34+ cells collected during apheresis.</description>
          <population>Full Analysis Set (FAS) includes all participants who received at least 1 dose of plerixafor.</population>
          <units>CD34+ cells (*10^6 / kg)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4" lower_limit="0.9" upper_limit="14.1"/>
                    <measurement group_id="O2" value="6.4" lower_limit="2.5" upper_limit="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Fold Increase in the Number of CD34+ Cells After Plerixafor Administration</title>
        <description>Fold Increase = (Pre-Apheresis CD34+ cells/Pre-Plerixafor CD34+ cells).</description>
        <time_frame>Days 4-5</time_frame>
        <population>Evaluable population of participants with peripheral blood CD34+ measurements on Days 4 and 5.</population>
        <group_list>
          <group group_id="O1">
            <title>G-CSF and Plerixafor</title>
            <description>Participants with CD20- lymphoma received granulocyte colony-stimulating factor (G-CSF) and plerixafor</description>
          </group>
          <group group_id="O2">
            <title>G-CSF and Plerixafor + Rituximab</title>
            <description>Participants with CD20+ lymphoma received rituximab, G-CSF, and plerixafor</description>
          </group>
        </group_list>
        <measure>
          <title>Median Fold Increase in the Number of CD34+ Cells After Plerixafor Administration</title>
          <description>Fold Increase = (Pre-Apheresis CD34+ cells/Pre-Plerixafor CD34+ cells).</description>
          <population>Evaluable population of participants with peripheral blood CD34+ measurements on Days 4 and 5.</population>
          <units>fold increase</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" lower_limit="1.6" upper_limit="1321.3"/>
                    <measurement group_id="O2" value="2.5" lower_limit="1.6" upper_limit="68.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Number of Apheresis Days Required to Reach a Minimum of 3*10^6 CD34+ Cells/kg</title>
        <description>Median number of apheresis days in each treatment arm to collect a minimum of 3*10^6 CD34+ cells/kg.</description>
        <time_frame>Days 5-8</time_frame>
        <population>Evaluable population of participants who achieved ≥3*10^cells/kg collected during apheresis.</population>
        <group_list>
          <group group_id="O1">
            <title>G-CSF and Plerixafor</title>
            <description>Participants with CD20- lymphoma received granulocyte colony-stimulating factor (G-CSF) and plerixafor</description>
          </group>
          <group group_id="O2">
            <title>G-CSF and Plerixafor + Rituximab</title>
            <description>Participants with CD20+ lymphoma received rituximab, G-CSF, and plerixafor</description>
          </group>
        </group_list>
        <measure>
          <title>Median Number of Apheresis Days Required to Reach a Minimum of 3*10^6 CD34+ Cells/kg</title>
          <description>Median number of apheresis days in each treatment arm to collect a minimum of 3*10^6 CD34+ cells/kg.</description>
          <population>Evaluable population of participants who achieved ≥3*10^cells/kg collected during apheresis.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="1.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Number of Apheresis Days Required to Reach the Target of 5*10^6 CD34+ Cells/kg</title>
        <description>Median number of apheresis days in each treatment arm to reach the target of 5*10^6 CD34+ cells/kg.</description>
        <time_frame>Days 5-8</time_frame>
        <population>Evaluable population of participants who achieved ≥5*10^cells/kg collected during apheresis.</population>
        <group_list>
          <group group_id="O1">
            <title>G-CSF and Plerixafor</title>
            <description>Participants with CD20- lymphoma received granulocyte colony-stimulating factor (G-CSF) and plerixafor</description>
          </group>
          <group group_id="O2">
            <title>G-CSF and Plerixafor + Rituximab</title>
            <description>Participants with CD20+ lymphoma received rituximab, G-CSF, and plerixafor</description>
          </group>
        </group_list>
        <measure>
          <title>Median Number of Apheresis Days Required to Reach the Target of 5*10^6 CD34+ Cells/kg</title>
          <description>Median number of apheresis days in each treatment arm to reach the target of 5*10^6 CD34+ cells/kg.</description>
          <population>Evaluable population of participants who achieved ≥5*10^cells/kg collected during apheresis.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="4.0"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Number of Days to Polymorphonuclear Leukocyte (PMN) Engraftment</title>
        <description>Median number of days from transplantation to PMN engraftment which was defined as PMN counts ≥0.5*10^9/L for 3 consecutive days or ≥1.0*10^9/L for 1 day. Time to engraftment corresponded to the first day that the criteria were met.</description>
        <time_frame>Days post transplantation (approximately Day 40)</time_frame>
        <population>Evaluable population of participants who received a stem cell transplant and had PMN engraftment</population>
        <group_list>
          <group group_id="O1">
            <title>G-CSF and Plerixafor</title>
            <description>Participants with CD20- lymphoma received granulocyte colony-stimulating factor (G-CSF) and plerixafor</description>
          </group>
          <group group_id="O2">
            <title>G-CSF and Plerixafor + Rituximab</title>
            <description>Participants with CD20+ lymphoma received rituximab, G-CSF, and plerixafor</description>
          </group>
        </group_list>
        <measure>
          <title>Median Number of Days to Polymorphonuclear Leukocyte (PMN) Engraftment</title>
          <description>Median number of days from transplantation to PMN engraftment which was defined as PMN counts ≥0.5*10^9/L for 3 consecutive days or ≥1.0*10^9/L for 1 day. Time to engraftment corresponded to the first day that the criteria were met.</description>
          <population>Evaluable population of participants who received a stem cell transplant and had PMN engraftment</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.0" lower_limit="11.0" upper_limit="21.0"/>
                    <measurement group_id="O2" value="13.5" lower_limit="11.0" upper_limit="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Number of Days to Platelet (PLT) Engraftment</title>
        <description>Median number of days from transplantation to PLT engraftment which was defined as platelet counts ≥20*10^9/L without transfusion for the preceding 7 days or platelet counts ≥50*10^9/L for one day. Time to engraftment corresponded to the first day that the criteria were met.</description>
        <time_frame>Days post transplantation (approximately Day 40)</time_frame>
        <population>Evaluable population of participants who received a stem cell transplant and had PLT engraftment.</population>
        <group_list>
          <group group_id="O1">
            <title>G-CSF and Plerixafor</title>
            <description>Participants with CD20- lymphoma received granulocyte colony-stimulating factor (G-CSF) and plerixafor</description>
          </group>
          <group group_id="O2">
            <title>G-CSF and Plerixafor + Rituximab</title>
            <description>Participants with CD20+ lymphoma received rituximab, G-CSF, and plerixafor</description>
          </group>
        </group_list>
        <measure>
          <title>Median Number of Days to Platelet (PLT) Engraftment</title>
          <description>Median number of days from transplantation to PLT engraftment which was defined as platelet counts ≥20*10^9/L without transfusion for the preceding 7 days or platelet counts ≥50*10^9/L for one day. Time to engraftment corresponded to the first day that the criteria were met.</description>
          <population>Evaluable population of participants who received a stem cell transplant and had PLT engraftment.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.0" lower_limit="13.0" upper_limit="31.0"/>
                    <measurement group_id="O2" value="22.0" lower_limit="16.0" upper_limit="28.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Number of Days to Lymphocyte Engraftment</title>
        <description>Median number of days from transplantation to lymphocyte engraftment which was defined as lymphocyte counts ≥5*10^8/L. Time to engraftment corresponded to the first day that criteria were met.</description>
        <time_frame>Days post transplantation (approximately Day 40)</time_frame>
        <population>Evaluable population of participants who received a stem cell transplant and had lymphocyte engraftment.</population>
        <group_list>
          <group group_id="O1">
            <title>G-CSF and Plerixafor</title>
            <description>Participants with CD20- lymphoma received granulocyte colony-stimulating factor (G-CSF) and plerixafor</description>
          </group>
          <group group_id="O2">
            <title>G-CSF and Plerixafor + Rituximab</title>
            <description>Participants with CD20+ lymphoma received rituximab, G-CSF, and plerixafor</description>
          </group>
        </group_list>
        <measure>
          <title>Median Number of Days to Lymphocyte Engraftment</title>
          <description>Median number of days from transplantation to lymphocyte engraftment which was defined as lymphocyte counts ≥5*10^8/L. Time to engraftment corresponded to the first day that criteria were met.</description>
          <population>Evaluable population of participants who received a stem cell transplant and had lymphocyte engraftment.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.5" lower_limit="9.0" upper_limit="32.0"/>
                    <measurement group_id="O2" value="14.0" lower_limit="7.0" upper_limit="22.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Level of CD19+CD2-CD14- B-cells Six Months Post-Transplant</title>
        <time_frame>Approximately 7 months (6 months post-transplant)</time_frame>
        <population>Evaluable population of participants who received a stem cell transplant and had assessment performed 6 months post-transplant.</population>
        <group_list>
          <group group_id="O1">
            <title>G-CSF and Plerixafor</title>
            <description>Participants with CD20- lymphoma received granulocyte colony-stimulating factor (G-CSF) and plerixafor</description>
          </group>
          <group group_id="O2">
            <title>G-CSF and Plerixafor + Rituximab</title>
            <description>Participants with CD20+ lymphoma received rituximab, G-CSF, and plerixafor</description>
          </group>
        </group_list>
        <measure>
          <title>Median Level of CD19+CD2-CD14- B-cells Six Months Post-Transplant</title>
          <population>Evaluable population of participants who received a stem cell transplant and had assessment performed 6 months post-transplant.</population>
          <units>cells / μL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="155.00" lower_limit="61.00" upper_limit="311.00"/>
                    <measurement group_id="O2" value="0.50" lower_limit="0.00" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Level of CD19+CD2-CD14- B-cells Twelve Months Post-Transplant</title>
        <time_frame>13 months (12 months post-transplant)</time_frame>
        <population>Evaluable population of participants who received a stem cell transplant and had assessment performed 12 months post-transplant.</population>
        <group_list>
          <group group_id="O1">
            <title>G-CSF and Plerixafor</title>
            <description>Participants with CD20- lymphoma received granulocyte colony-stimulating factor (G-CSF) and plerixafor</description>
          </group>
          <group group_id="O2">
            <title>G-CSF and Plerixafor + Rituximab</title>
            <description>Participants with CD20+ lymphoma received rituximab, G-CSF, and plerixafor</description>
          </group>
        </group_list>
        <measure>
          <title>Median Level of CD19+CD2-CD14- B-cells Twelve Months Post-Transplant</title>
          <population>Evaluable population of participants who received a stem cell transplant and had assessment performed 12 months post-transplant.</population>
          <units>cells / μL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="322.50" lower_limit="189.00" upper_limit="518.00"/>
                    <measurement group_id="O2" value="236.00" lower_limit="0.00" upper_limit="457.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percentage of CD19+CD3-CD14- B-cells of the Total Cells on the First Apheresis Day</title>
        <time_frame>Day 5</time_frame>
        <population>Full Analysis Set (FAS) includes all participants who received at least 1 dose of plerixafor.</population>
        <group_list>
          <group group_id="O1">
            <title>G-CSF and Plerixafor</title>
            <description>Participants with CD20- lymphoma received granulocyte colony-stimulating factor (G-CSF) and plerixafor</description>
          </group>
          <group group_id="O2">
            <title>G-CSF and Plerixafor + Rituximab</title>
            <description>Participants with CD20+ lymphoma received rituximab, G-CSF, and plerixafor</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of CD19+CD3-CD14- B-cells of the Total Cells on the First Apheresis Day</title>
          <population>Full Analysis Set (FAS) includes all participants who received at least 1 dose of plerixafor.</population>
          <units>percentage of total cells</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.83" lower_limit="0.07" upper_limit="7.86"/>
                    <measurement group_id="O2" value="0.09" lower_limit="0.01" upper_limit="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Durable Engraftment 12 Months After Transplantation</title>
        <description>The number of participants maintaining a durable graft 12 months after autologous transplantation. A durable graft is defined as the maintenance of normal blood counts.</description>
        <time_frame>Approximately 13 months (12 months post-transplant )</time_frame>
        <population>Evaluable population of participants who received a stem cell transplant and had a 12-month assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>G-CSF and Plerixafor</title>
            <description>Participants with CD20- lymphoma received granulocyte colony-stimulating factor (G-CSF) and plerixafor</description>
          </group>
          <group group_id="O2">
            <title>G-CSF and Plerixafor + Rituximab</title>
            <description>Participants with CD20+ lymphoma received rituximab, G-CSF, and plerixafor</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Durable Engraftment 12 Months After Transplantation</title>
          <description>The number of participants maintaining a durable graft 12 months after autologous transplantation. A durable graft is defined as the maintenance of normal blood counts.</description>
          <population>Evaluable population of participants who received a stem cell transplant and had a 12-month assessment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>First day of G-CSF mobilization to the day prior to chemotherapy/ablative treatment in preparation for the first transplant. This timeframe includes G-CSF and plerixafor administration (rituximab if applicable), and the rest period.</time_frame>
      <desc>In the event a single participant has experienced both a serious and a non-serious form of the same adverse event term, the individual has been included in the numerator (&quot;number of affected participants&quot;) of both adverse event tables.
Each AE table includes all events, regardless of reported relationship to study treatment or grade.</desc>
      <group_list>
        <group group_id="E1">
          <title>G-CSF and Plerixafor</title>
          <description>Participants with CD20- lymphoma received granulocyte colony-stimulating factor (G-CSF) and plerixafor</description>
        </group>
        <group group_id="E2">
          <title>G-CSF and Plerixafor + Rituximab</title>
          <description>Participants with CD20+ lymphoma received rituximab, G-CSF, and plerixafor</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia oral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Paraesthesia oral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Catheter site discharge</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Catheter site erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Catheter site pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Injection site irritation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Injection site paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood lactate dehydrogenase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Urine pH increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Heart rate irregular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Respiratory alkalosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia facial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>In multi-site studies, PI can publish after Genzyme publishes or 18 months after study completion. PI gives Genzyme a draft 60 days before publication. Genzyme can ask that confidential information be removed, and can defer publication another 60 days upon notifying PI that it will file a patent application on inventions contained in the draft.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Information</name_or_title>
      <organization>Genzyme</organization>
      <email>medinfo@genzyme.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

